Human Ultracell V IM |
Human Ultracell V Oral |
Human Citoplacell 3G |
Revercell 3G |
Cellorgane Multi-Complex 3G ![]() |
Androcell 3G |
Biofemin 3G |
Bioenzym 3G |
Celltox 3G |
Mekenz H7 3G |
Cellorgane Man |
Cellorgane Woman |
Formula 1 Skin & Muscle |
Formula 2 Liver |
Formula 3 Heart-Artery-Vein |
Formula 4 Bone-Cartilage |
Formula 5 Kidney - Nephrons |
Formula 6 Lungs |
Formula 7 Brain-Hypothalamus-Pituitary |
Formula 8 Adrenal Gland |
Formula 9 Thymus - Spleen |
Formula 10 Pancreas |
Formula 11 Esophagus-Stomach-Intestines |
Formula 12 Thyroid |
Cardiologists, Internists, and Internal Medicine
Hypertension (HTN) is a chronic disease characterized by a gradual elevation in the blood pressure of the arteries. Although there is no strict threshold that allows us to define the line separating risk and safety, according to international consensus a sustained systolic pressure above 139 mmHg or a sustained diastolic pressure above 89 mmHg are associated with a measurable increase in the risk of atherosclerosis and are thus considered to be clinically significant hypertension.
Hypertension is associated with considerably elevated rates of morbidity and mortality. For this reason, it is considered to be one of the most important public health problems, especially in developed countries, where it affects nearly one billion people worldwide. Hypertension is an asymptomatic disease and easy to detect, but can lead to serious and even lethal complications if not treated on time.
Chronic hypertension is the most important modifiable risk factor for the development of cardiovascular diseases, as well as for cerebrovascular and renal diseases. We also know that men have a higher predisposition for developing hypertension that women. This situation changes when women reach menopause.
Several risk factors have been associated with the development of cardiovascular diseases. Among these is oxidative stress, which leads to elevated concentrations of lipid peroxidation products.
In these cases that cardiac tissue wears out and deteriorates, cellular regeneration becomes of vital importance. It is necessary to apply the organ’s cellular extracts in order to revitalize the worn out muscle.
Protocol 1 (Moderate HTN)
Bioenzym tablets, take 2 tablets in the morning (on an empty stomach) and 2 tablets at night (on an empty stomach). Treatment should be taken continuously for at least 3 months, and then re-evaluate.
Protocol 2 (Preventive, Moderate HTN)
Cellorgane Multi-complex tablets. Take 2 tablets in the morning (on an empty stomach) and 2 tablets at night (on an empty stomach). Treatment should be taken continuously for at least 6 months, and then re-evaluate.
Bioenzym tablets, take 2 tablets in the morning (on an empty stomach) and 2 tablets at night (on an empty stomach). Treatment should be taken continuously for at least 3 months, and then re-evaluate.
Protocol 3 (Moderate HTN with Cardiovascular Compromise)
Administer 2 ml daily by deep intramuscular injection for 5 days, rest 2 days, and adminis-ter another complete treatment course of 2 ml daily for 5 days (two boxes). Treatment should be repeated after 6 months.
Cellorgane Multi-complex tablets. Take 2 tablets in the morning (on an empty stomach) and 2 tablets in the evening (on an empty stomach). Treatment should be taken continu-ously for at least 6 months, and then re-evaluate.
Protocol 4 (Severe HTN)
Administer 2 ml daily by deep intramuscular injection for 5 days, rest 2 days, and adminis-ter another complete treatment of 2 ml daily for 5 days (two boxes). Treatment should be repeated after 6 months.
Cellorgane Multi-complex tablets. Take 2 tablets in the morning (on an empty stomach) and 2 tablets in the evening (on an empty stomach). Treatment should be taken continu-ously for at least 6 months, and then re-evaluate.
After finishing Cellorgane Multi-complex No. 3, administer 2 ml daily by deep intramuscular injection for 5 days, rest 2 days, and administer another complete treatment course of 2 ml daily for 5 days (two boxes). Acts as Multi-organ support. Treatment should be repeated after 6 months.
Bioenzym tablets, take 2 tablets in the morning (on an empty stomach) and 2 tablets at night (on an empty stomach). Treatment should be taken continuously for at least 3 months, and then re-evaluate.
Protocol 5 (HTN + Risk of Metabolic Syndrome)
To be administered concurrently with Cellorgane Multi-complex No. 3 Heart, Arteries, and Veins Injectable, one white capsule in the morning, one white/red capsule in the afternoon, and one red capsule at night before meals, continuously for six months, and then re-evaluate.
Biocell Ultravital™ researches and develops innovative, 100% natural, pharmaceutical-grade bioproducts, on an exclusive basis worldwide. These products optimise cell nutrition and energy, producing a preventative and curative action which, in addition to treating pre-symptoms and symptoms by means of cell renewal, refuels and corrects the cell structure of tissues and organs, preventing the appearance of the functional stress loads which give rise to poor cell formation, degenerative diseases, and their after-effects.
Product developed under pharmaceutical control according to European CE standards. Made in the EC by Biocell Laboratory France, licensed and authorized by Biocell Ultravital GmbH, Switzerland.
This website is governed by applicable laws and government regulations. Please see our Privacy Policy.
Use of this site constitutes your consent to application of such laws and regulations.
» Home
» Training for Doctors
» Analysis Cellular Aging
» Medical News
» Medical Chat Live
» Clinical Protocos
» Medical Questions
» PDF Brochure
» Contact